Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials (Q33857346)

29 July 2017

0 references

1 reference

title

Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials (English)

1 reference

29 July 2017

1 reference

1 reference

K Wahlbeck

1

0 references

author name string

M V Cheine

series ordinal

2

1 reference

29 July 2017

S Gilbody

series ordinal

3

1 reference

29 July 2017

J Ahonen

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

29 July 2017

published in

Schizophrenia Research

1 reference

29 July 2017

volume

41

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

341-347

1 reference

Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

One more look at propranolol for the treatment of refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Defining treatment refractoriness in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Meta-analyses using individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Publication bias in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Diagnostic Criteria for Use in Psychiatric Research

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

A trial of propranolol in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

The science of reviewing research

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Propranolol as an adjunct to the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Propranolol in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900069-9

7 January 2021

10.1016/S0920-9964(99)00069-9

Identifiers

DOI

1 reference

29 July 2017

1 reference